# FDA WARNING_LETTER - Pharmacy2Home/LandiCom Holding LTD - December 13, 2021

Source: https://www.keypedia.com/records/warning_letter/pharmacy2homelandicom-holding-ltd/2ced2cc1-73e9-49c4-bd56-8835ff64d0b7

> FDA WARNING_LETTER for Pharmacy2Home/LandiCom Holding LTD on December 13, 2021. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: Pharmacy2Home/LandiCom Holding LTD
- Inspection Date: 2021-12-13
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research
- Summary: On February 3, 2022, the FDA issued a Warning Letter to www.pharmacy2home.com following a December 13, 2021, review of their website. The FDA observed the website offering drug products for sale in the U.S. that claim to mitigate, prevent, treat, diagnose, or cure COVID-19 and other diseases.

The FDA determined these products are unapproved new drugs, violating section 505(a) of the FD&C Act [21 U.S.C. § 355(a)], and misbranded drugs under section 502 of the FD&C Act [21 U.S.C. § 352]. Specific examples include "Chloroquine (CoronaVirus Covid-19)," "Antiflu 75 mg (Oseltamivir)," a "CoronaVirus pack" containing oseltamivir, ribavirin, and lopinavir + ritonavir, and "Ivermectin 12mg (Covid/Corona)." These drugs are not FDA-approved for their advertised uses, particularly for COVID-19, and lack adequate directions for layperson use, as they are prescription drugs.

The introduction of these products into interstate commerce is prohibited under sections 301(a) and 301(d) of the FD&C Act [21 U.S.C. §

## Related Officers

- [Director](https://www.keypedia.com/people/donald-d-ashley/060f0dda-e6e8-4f9c-97e7-f540d523d902)

Company: https://www.keypedia.com/companies/pharmacy2homelandicom-holding-ltd/e35f42ed-a649-43e7-8747-885c2d77a68d

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c